Cargando…

Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder

The selective serotonin reuptake inhibitor escitalopram (ESC) is indicated for the treatment of major depressive disorder (MDD) and of generalized anxiety disorder (GAD). Monitoring of blood levels (BLs) is strongly indicated due to ESC’s high interindividual pharmacokinetic variability. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hart, X. M., Heesen, S., Schmitz, C. N., Dörfler, S., Wedekind, D., Gründer, G., Hiemke, C., Havemann-Reinecke, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958172/
https://www.ncbi.nlm.nih.gov/pubmed/36207527
http://dx.doi.org/10.1007/s00406-022-01491-9
_version_ 1784894969717194752
author Hart, X. M.
Heesen, S.
Schmitz, C. N.
Dörfler, S.
Wedekind, D.
Gründer, G.
Hiemke, C.
Havemann-Reinecke, U.
author_facet Hart, X. M.
Heesen, S.
Schmitz, C. N.
Dörfler, S.
Wedekind, D.
Gründer, G.
Hiemke, C.
Havemann-Reinecke, U.
author_sort Hart, X. M.
collection PubMed
description The selective serotonin reuptake inhibitor escitalopram (ESC) is indicated for the treatment of major depressive disorder (MDD) and of generalized anxiety disorder (GAD). Monitoring of blood levels (BLs) is strongly indicated due to ESC’s high interindividual pharmacokinetic variability. The aim of this study was to analyse clinical efficacy and pharmacokinetic influences on ESC BLs, in patients with depressive disorder alone and with comorbid alcohol or benzodiazepine use disorder. Data were collected from patients treated under naturalistic conditions for whom Therapeutic Drug Monitoring (TDM) was requested to guide antidepressant drug therapy and analysed retrospectively. Particular emphasis was given to patients with alcohol or benzodiazepine use disorder. Responders according to the clinical global impression (CGI) scale were compared with nonresponders for their ESC blood level (BL). The patient sample included 344 patients from 16 psychiatric hospitals in Germany. Influencing factors that could explain 22% of ESC BLs were dose, sex and age. Variability was high between individuals, and doses up to 40 mg were common in real-world settings. Patients treated with ESC monotherapy who responded showed a trend towards higher BLs compared to nonresponders with a concentration of 15 ng/mL separating both groups. Pathological changes in liver function (indicated by elevated GGT in combination with an AST/ALT ratio ≥ 1) resulted in higher dose-corrected ESC concentrations. Influencing factors that could explain 22% of ESC blood levels were dose, sex, and age. Our findings confirm the currently recommended lower threshold level and support the need for standard TDM analyses in everyday clinical practice. The ICD 10 diagnosis alcohol dependence alone does not lead to pharmacokinetic changes in the metabolism of ESC, but altered liver function does. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00406-022-01491-9.
format Online
Article
Text
id pubmed-9958172
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-99581722023-02-26 Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder Hart, X. M. Heesen, S. Schmitz, C. N. Dörfler, S. Wedekind, D. Gründer, G. Hiemke, C. Havemann-Reinecke, U. Eur Arch Psychiatry Clin Neurosci Original Paper The selective serotonin reuptake inhibitor escitalopram (ESC) is indicated for the treatment of major depressive disorder (MDD) and of generalized anxiety disorder (GAD). Monitoring of blood levels (BLs) is strongly indicated due to ESC’s high interindividual pharmacokinetic variability. The aim of this study was to analyse clinical efficacy and pharmacokinetic influences on ESC BLs, in patients with depressive disorder alone and with comorbid alcohol or benzodiazepine use disorder. Data were collected from patients treated under naturalistic conditions for whom Therapeutic Drug Monitoring (TDM) was requested to guide antidepressant drug therapy and analysed retrospectively. Particular emphasis was given to patients with alcohol or benzodiazepine use disorder. Responders according to the clinical global impression (CGI) scale were compared with nonresponders for their ESC blood level (BL). The patient sample included 344 patients from 16 psychiatric hospitals in Germany. Influencing factors that could explain 22% of ESC BLs were dose, sex and age. Variability was high between individuals, and doses up to 40 mg were common in real-world settings. Patients treated with ESC monotherapy who responded showed a trend towards higher BLs compared to nonresponders with a concentration of 15 ng/mL separating both groups. Pathological changes in liver function (indicated by elevated GGT in combination with an AST/ALT ratio ≥ 1) resulted in higher dose-corrected ESC concentrations. Influencing factors that could explain 22% of ESC blood levels were dose, sex, and age. Our findings confirm the currently recommended lower threshold level and support the need for standard TDM analyses in everyday clinical practice. The ICD 10 diagnosis alcohol dependence alone does not lead to pharmacokinetic changes in the metabolism of ESC, but altered liver function does. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00406-022-01491-9. Springer Berlin Heidelberg 2022-10-07 2023 /pmc/articles/PMC9958172/ /pubmed/36207527 http://dx.doi.org/10.1007/s00406-022-01491-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Hart, X. M.
Heesen, S.
Schmitz, C. N.
Dörfler, S.
Wedekind, D.
Gründer, G.
Hiemke, C.
Havemann-Reinecke, U.
Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder
title Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder
title_full Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder
title_fullStr Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder
title_full_unstemmed Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder
title_short Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder
title_sort concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958172/
https://www.ncbi.nlm.nih.gov/pubmed/36207527
http://dx.doi.org/10.1007/s00406-022-01491-9
work_keys_str_mv AT hartxm concentrationsofescitalopraminbloodofpatientstreatedinanaturalisticsettingfocusonpatientswithalcoholandbenzodiazepineusedisorder
AT heesens concentrationsofescitalopraminbloodofpatientstreatedinanaturalisticsettingfocusonpatientswithalcoholandbenzodiazepineusedisorder
AT schmitzcn concentrationsofescitalopraminbloodofpatientstreatedinanaturalisticsettingfocusonpatientswithalcoholandbenzodiazepineusedisorder
AT dorflers concentrationsofescitalopraminbloodofpatientstreatedinanaturalisticsettingfocusonpatientswithalcoholandbenzodiazepineusedisorder
AT wedekindd concentrationsofescitalopraminbloodofpatientstreatedinanaturalisticsettingfocusonpatientswithalcoholandbenzodiazepineusedisorder
AT grunderg concentrationsofescitalopraminbloodofpatientstreatedinanaturalisticsettingfocusonpatientswithalcoholandbenzodiazepineusedisorder
AT hiemkec concentrationsofescitalopraminbloodofpatientstreatedinanaturalisticsettingfocusonpatientswithalcoholandbenzodiazepineusedisorder
AT havemannreineckeu concentrationsofescitalopraminbloodofpatientstreatedinanaturalisticsettingfocusonpatientswithalcoholandbenzodiazepineusedisorder